GSK plc (LON:GSK) Insider Sells £1,753,088.09 in Stock

GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley sold 120,653 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.28), for a total transaction of £1,753,088.09 ($2,205,419.66).

GSK Trading Down 0.7 %

GSK stock traded down GBX 9.50 ($0.12) during mid-day trading on Friday, reaching GBX 1,435 ($18.05). 5,979,453 shares of the stock traded hands, compared to its average volume of 26,154,219. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK plc has a one year low of GBX 1,282.50 ($16.13) and a one year high of GBX 1,823.50 ($22.94). The stock has a market capitalization of £58.23 billion, a PE ratio of 23.18, a PEG ratio of 1.24 and a beta of 0.31. The business has a 50-day moving average price of GBX 1,369.25 and a two-hundred day moving average price of GBX 1,453.87.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts expect that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analysts Forecast Growth

GSK has been the topic of several research reports. Berenberg Bank reduced their price target on shares of GSK from GBX 1,820 ($22.90) to GBX 1,600 ($20.13) and set a "buy" rating on the stock in a research report on Friday, November 29th. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of GBX 1,805.83 ($22.72).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.